

## Pharmaceutical Applications of EPR

II. Optimizing Stability and Shelf-Life

Forced degradation (stress testing) is routinely used in pharmaceutical development to predict the stability of drug products that affects purity, effectiveness, and safety. In stress testing the drug product is exposed to heat, light or chemical agents with the goals being:

- understanding degradation pathways
- determining the intrinsic stability and shelf-life
- developing stable formulations
- evaluating antioxidant efficiency

Product degradation often involves a free radical pathway therefore identifying the radical intermediates is extremely important. In addition, antioxidants' efficiency in drug formulations is characterized by the ability to scavenge the free radicals and eliminate stability issues.

Electron Paramagnetic Resonance (EPR) spectroscopy can successfully detect and monitor short-lived free radicals produced during stress testing via chemical, thermal, or photochemical reactions. EPR can determine radical scavenging effectiveness and efficiency of antioxidants.

## Challenge


Knowledge of stability and shelf-life of APIs and excipients is required for selecting a proper drug formulation. Stress testing is required by ICH guidelines.

## Solution

The Bruker EMXnano benchtop EPR spectrometer package

- Predicts long-term stability (photo-, thermo-, chemical) of drug products by monitoring processes that produce and involve free radicals
- Uses minimal sample quantities in early development phase of new APIs
- Determines the antioxidant efficiency to quench free radicals with well established assays






Antioxidant A is more effective than antioxidant B at quenching the free radicals in the drug formulation

## **EMXnano key features:**

- No prior EPR experience needed
- Video how-to-guide and startup kit
- Accurate results
- Superior sensitivity
- Ease of use
- Full workflow for measuring, analyzing and quantifying free radicals
- Compact foot print
- Low cost of ownership



Tablets 1 and 2 with low radical formation have better potential for drug development.

> **Bruker BioSpin** epr@bruker.com www.bruker.com/EMXnano